Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inositec AG
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.
Mattias Ivarsson, co-founder and CEO of Swiss biotech company Inositec, talks to Lucie Ellis, senior writer at Scrip, about the company's technology and progress since being founded in 2015.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools